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ABSTRACT | RESUMO 
Abstract: Hereditary Hemochromatosis (HH) is an autosomal recessive metabolic disease that leads 
to progressive iron loading of parenchymal cells, resulting in tissue damage and organ failure. The great 
majority of patients are homozygous for the mutation C282Y in the HFE gene, which encodes a non classical 
MHC-class I protein, whose role in iron homeostasis is not fully explained. The clinical presentation is 
heterogeneous, varying from a simple biochemical abnormality to a devastating iron overload disease. 
Immune mechanisms have been implicated in the clinical heterogeneity of HH. Previous studies have shown 
that patients with abnormally high CD4/CD8 ratios display a faster re-entry of iron into the serum transferrin 
pool after intensive phlebotomy treatment than patients without these abnormalities. Moreover, low numbers 
of CD8+ T cells observed in the peripheral blood of patients homozygous for the C282Y mutation correlates 
with higher hepatic tissue iron. Whether the low CD8+ T cell count directly contributes to the progression of 
iron accumulation or is simply associated with other genetic factors involved in iron metabolism is still not 
clarified and the mechanisms that regulate the numbers of CD8+ T lymphocytes need to be investigated. 
Using flow cytometry, we proposed to investigate if low numbers of CD8+ T lymphocytes observed in the 
blood of HH patients are related to cell cycle and/or apoptosis abnormalities. 
The population analyzed in this study was composed by HH patients homozygous for the C282Y 
mutation of the HFE gene from the Hemochromatosis Clinic from HSA/CHP and blood donors. For all the 
individuals, we performed the quantification of total peripheral blood T cells and CD4+ and CD8+ T cell 
populations, the quantification of the percentage of apoptotic peripheral blood CD8+ T cells and of CD4+ T 
cells, the quantification of the percentage of peripheral blood CD8+ T cells, of CD4+ T cells at the G0/G1, S 
and G2/M phases of the cell cycle, and measurement biochemical parameters of iron status. 
Although the present work could not provide an answer to the starting question on the possible 
mechanism underlying the defects in CD8+ T lymphocyte numbers in HH patients, it contributed, however, 
to better demonstrate the general marked differences in apoptosis and cell cycle markers between the 
subpopulations of CD4+ and CD8+ T lymphocytes, and permitted also to reveal, for the first time, an impact 
of systemic  iron parameters on T lymphocyte apoptosis, and some differences in cell cycle progression in 
HH patients. 
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Resumo: A Hemocromatose Hereditária (HH) representa um distúrbio metabólico, transmitido de 
forma autossómica recessiva, no qual a acumulação progressiva de ferro nas células parenquimatosas leva a 
lesão tecidular e disfunção orgânica. Na grande maioria, os doentes são homozigóticos para a mutação 
C282Y no gene HFE, que codifica uma proteína MHC classe I não clássica, e cujo papel na homeostasia do 
ferro não está bem esclarecido. A apresentação clínica da doença é muito variável, desde a alteração 
bioquímica isolada, até a disfunção multiorgânica, e o sistema imune está envolvido na modulação desta 
heterogeneidade. Estudos prévios demonstraram que doentes com razões CD4+/CD8+ mais elevadas 
mostram uma reacumulação de ferro mais rápida após tratamento intensivo com flebotomias, em 
comparação com doentes com razões normais. Níveis mais baixos de linfócitos T CD8+ no sangue periférico 
destes doentes correlacionam-se com níveis mais elevados de ferro no fígado. Não é claro ainda se o baixo 
número de linfócitos T CD8+ contribui diretamente para a acumulação progressiva de ferro, ou está apenas 
relacionado com outros factores genéticos envolvidos no seu metabolismo, devendo investigar-se os 
mecanismos que regulam estas contagens celulares. Recorrendo á citometria de fluxo, propusemo-nos 
analisar se os baixos níveis de linfócitos T CD8+ observados no sangue periférico de doentes com HH se 
correlacionam com alterações no ciclo celular ou apoptose destas células. 
A população analisada neste estudo foi composta por doentes com HH homozigóticos para a 
mutação C282Y do gene HFE, provenientes da Consulta de Hemocromatose do HSA / CHP e por dadores de 
sangue. Para todos os indivíduos, foi realizada a quantificação das células T totais no sangue periférico e das 
populações de células T CD4 + e CD8 +, a quantificação da percentagem de células CD8 + T e de células T 
CD4 + apoptóticas do sangue periférico e a quantificação da percentagem de células T CD8 + e de células T 
CD4 + do sangue periférico nas fases G0/G1, S e G2 /M do ciclo celular. Foram ainda medidos os 
parâmetros bioquímicos do ferro.  
Embora o presente trabalho não possa dar uma resposta à pergunta de partida sobre o possível 
mecanismo subjacente às variações do número de linfócitos T CD8 + em doentes com HH, contribuiu, no 
entanto, para demonstrar melhor as diferenças marcadas na apoptose e marcadores do ciclo celular entre as 
subpopulações de linfócitos T CD4 + e CD8 +, e permitiu também, pela primeira vez, revelar o impacto de 
parâmetros de ferro sistémico na apoptose de linfócitos T, e algumas diferenças na progressão do ciclo 
celular em doentes com HH. 
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TITLE | TÍTULO 
Cell cycle and apoptosis in T cells from Hereditary Hemochromatosis patients 
 
 
INTERVENIENTS | INTERVENIENTES NO PROJETO 
Institutions, Departments and Services | Instituições, Departamentos e Serviços 
 Centro Hospitalar do Porto (CHP) 
o Hospital de Santo António (HSA) 
 Departamento de Medicina (DM) 
  Serviço de Hematologia Clínica (SHC) 
Research team | Equipa de Investigação 
Constitution | Constituição 
Student | Aluno 
 Maria João Silva: Aluna da Disciplina de Iniciação à Investigação Clínica (DIIC) do Curso de 
Mestrado Integrado em Medicina (MIM) do ICBAS/UP. 
Supervisors | Orientadores 
 Prof. Doutora Graça Porto: Médica, Imunohemoterapeuta, Chefe de Serviço, Serviço de 
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(Supervisor). 
 Doutor Jorge Pinto: Investigador do IBMC (Co-supervisor). 
Discipline supervisor | Supervisores 
 Prof. Doutora Margarida Lima: Médica, Imunohemoterapeuta, Assistente Hospitalar Graduada do 
SHC do HSA/CHP; Responsável pelo Laboratório de Citometria (LC) do SHC do HSA/CHP; 
Professora Auxiliar Convidada do ICBAS/UP; Regente da DIIC. 
Other investigators | Outros investigadores 
 Dra. Sónia Fonseca, Técnica de Diagnóstico e Terapêutica (TDT) do LC do SHC do HSA/CHP. 
 Enf. Graça Melo, Enfermeira da Consulta de Hemocromatose do SHC do HSA/CHP. 
Functions and responsabilities | Funções e responsabilidades 
The conception and formulation of the proposal, as well as the execution of the project are 
responsibilities of the student. The supervisor will monitor the formulation of the proposal, the 
execution of the project and the analysis and interpretation of the results. The discipline supervisor 
will supervise all the steps of the project, including the conception, the implementation, and the 
presentation of the results. The follow investigators will collaborate in specific tasks of the project, 
and described forward.  
Time dedicated to the project | Tempo dedicado ao projeto 
 Total: 5,05 persons*month 
 Student: 10% - 22 months (1 x 0,10 x 22 = 2,2 persons*month) 
 Supervisors (x2): 2,5% - 22 months (2 x 0,025 x 22 = 1,1 persons*month) 
 Disciple supervisor: 2,5% - 22 months (1 x 0,025 x 22 = 0,55 persons*month) 
 Other investigators (x2): 10% - 6 months (2 x 0,10 x 6 = 1,2 persons*month) 
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SCIENTIFIC PLAN | PLANO CIENTÍFICO 
Introduction | Introdução 
Hereditary Hemochromatosis (HH) is one of the most common hereditary metabolic diseases in 
Caucasians (Cardoso CS et al, 2001). In this clinical/pathological entity progressive iron loading of 
parenchymal cells leads to tissue damage and organ failure, in a characteristic pattern that affects liver, 
pancreas, joints, skin, hypophysis or heart (reviewed by Porto G et al, 2008).  
The great majority of patients are homozygous for the mutation C282Y in the HFE gene, assigned to 
the short arm of chromosome 6, that encodes a non classical MHC-class I protein, whose role in iron 
homeostasis is not fully explained (Feder JN et al, 1996). This mutation is inherited in an autosomal 
recessive pattern, but other genetic defects involved in cellular and systemic iron metabolism are expected to 
interact with HFE. In the north of Portugal the allele frequency of the C282Y mutation is 0.058, 
corresponding to a frequency of homozygous of 0.8%. 
The clinical presentation is very heterogeneous, varying from a simple biochemical abnormality to a 
full-blown picture of devastating iron overload disease. In order to be considered severe iron overload it is 
necessary the demonstration of abnormally increased hepatic iron stores (Porto G et al, 2008). It is of great 
interest to understand what modulates this clinic variability, leading us to the best therapeutic approach. 
Immune mechanisms have been implicated in the clinical heterogeneity of HH (Porto G & De Sousa 
M, 2007). The postulate that immunological system could have a role in monitoring tissue iron toxicity, as 
part of its surveillance function, was first described by De Sousa in 1978, based on her observations of 
lymphocyte traffic and positioning (De Sousa M, 1978). Later studies have identified a correlation with other 
elements of immune system, as monocyte/macrophages and NK cells.  
A study performed in 1991 revealed that patients with abnormally high CD4/CD8 ratios (>2.9) 
displayed a faster re-entry of iron into the serum transferrin pool after intensive phlebotomy treatment than 
patients without those abnormalities (reviewed by Porto G et al, 2008). In 2001, a study performed 
specifically in patients homozygous for the C282Y mutation related low percentages of CD8+ T cells in the 
peripheral blood with higher levels of hepatic tissue iron (Cardoso EM et al, 2001). Several molecular and 
functional abnormalities, in addition to the counts were also identified in the populations of CD8+ T cells 
(reviewed by Porto G et al, 2008). These abnormalities are not described in secondary forms of iron 
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overload. The fact that anomalies are remarkably stable in each individual patient, that they are not corrected 
by phlebotomy treatment, and that they are observed in asymptomatic patients at young ages, favours the 
hypothesis that they are intrinsic to the genetic defect and not a consequence of the progressive iron overload 
(Porto G et al, 2007).The involvement of the MHC region on this regulation was first demonstrated in 
humans in 2004 (Cruz E et al, 2004), and later results support the notion that gene(s) in this region contribute 
both to the control of CD8+ T-cell numbers and the clinical heterogeneity observed in HH. Whether the 
identified phenotype of low CD8+ T cells directly contributes to the progression of iron accumulation or is 
simply associated with other genetic factors involved in iron metabolism needs to be investigated (Cruz E et 
al 2006a). 
The described abnormalities in lymphocyte populations were systematically found in the sub-
population of CD8+ T lymphocytes, but the association with total body iron stores is also reflected in the 
total lymphocyte counts (Porto G et al, 2007). Although no specific abnormalities have so far been found in 
CD4+ T lymphocytes, the possibility that they also might be present is not fully excluded. 
The mechanisms that regulate the numbers of lymphocytes in the peripheral blood are still not 
clarified. The control system of cell cycle has a main role on the regulation of the numbers of a certain 
population of cells. No studies have addressed before whether is there any alteration in cell cycle in 
lymphocytes from HH patients. The only described alteration is an adaptive response to a genotoxic agent 
(Porto B et al, 2009), reflected in a decrease in induced chromosome breakage. We might speculate if this 
correlates with cell cycle progression. 
Using flow cytometry it is possible to analyze the cell cycle, based on cellular deoxyribonucleic acid 
(DNA) content. The capacity for multiparametric measurement of large cell populations rapidly and 
accurately offered by cytometry has made this methodology indispensable in studies of cell proliferation and 
cell death (Darzynkiewiczab Z et al, 2001). A variety of flow cytometric methods to analyze the cell cycle 
progression, developed over the past three decades, reveals distribution of cells in three major phases of the 
cycle (G0/G1, S and G2/M) and makes it possible to detect apoptotic cells with fractional DNA content. The 
discrimination between quiescent (G0) and proliferating cells is achievable, based on the presence of 
proliferation-associated proteins.  
Using flow cytometry it is also possible to analyze apoptosis and a variety of flow cytometric 
methods to quantify apoptotic cells have been described. Staining with fluorochrome conjugated Annexin V 
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(due to phosphatidylserine externalization to the outer leaflet of the plasma membrane early during 
apoptosis) is typically used in conjunction with a fluorescent vital dye such as propidium iodide (PI) or 7-7-
Amino-Actinomycin D (7-AAD) to allow the identification and quantification of apoptotic cells (Annexin V 
positive / PI and 7-AAD negative).  
In this study we propose to investigate, by flow cytometry, if low numbers of CD8+ T lymphocytes 
observed in the blood of HH patients are related to cell cycle and/or apoptosis abnormalities. 
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Background and rationale of the study | Enquadramento e justificação do estudo 
The project supervisor, Prof. Graça Porto, is Consultant at the Clinical Hematology Service in HSA 
and the Responsible for the Hemochromatosis Clinic in this Service since 1985. This Outpatient Clinic has 
developed for the last 25 years as a specialized center for the diagnosis, treatment and prevention of 
Hemochromatosis and obtained its certification according to the ISO 9001:2000 standards in 2005.  The 
regular movement of the Clinic, that is open twice a week, is of about 1200 consultations/year, 
corresponding to an average number of 260 patients, most of them (40%) being cases of Hereditary 
Hemochromatosis. This allows an easy and efficient access to biological samples and clinical records from 
well characterized patients and families. Moreover, as part of the regular clinical work, the project supervisor 
is also involved in the observation and selection of regular blood donors at the Blood Bank, providing the 
opportunity of an easy recruitment for the study of healthy subjects from the normal population. 
Prof. Graça Porto is also the Director of a new research group at IBMC (BCRIB, Basic and Clinical 
Research on Iron Biology). The main objective of the group is to understand iron homeostasis through the 
investigation of the reciprocal functional interactions between Iron Metabolism & The Cells of the Immune 
System (IS), focusing on the basic questions: how do cells of the IS contribute to the regulation of systemic 
iron homeostasis and how is iron balance sensed by those cells? A major clinical impact of the present 
research is expected to be a deeper understanding of the pathophysiology of common or rare disorders of iron 
homeostasis, most genetically determined, eventually leading to the development of new markers of disease or 
new forms of treatment and/or prevention. The members of the proposing group have a long historical 
background of research in the former IBMC group “Iron Genes and the Immune System (IRIS)” headed by 
Maria de Sousa, having been actively involved in several main achievements, namely: 
1. The first demonstration that the clinical severity of iron overload in Hereditary Hemochromatosis 
(HH), the most common genetic disorder of iron overload, is related to CD8
+
 T lymphocyte numbers in the 
context of the Human Leukocyte Antigen (HLA) genotypes (Porto et al, Eu J Haematol 52:283-290, 1994; 
Porto et al, Hepatology 25:397-402, 1997; Cruz et al, Blood Cells Mol Dis; 37:33-39, 2006) 
2. The first evidence, in humans, that CD8
+
 T lymphocyte numbers are genetically determined in 
association with MHC-class I genetic markers (Cruz et al, Tissue Antigens;  64:25-34, 2004; Cruz et al, 
BMC Med Genet. 7:16, 2006, Vieira et al. Int J Immunogenet; 34:359-367, 2007) 
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3. The first evidence that lymphocytes express hepcidin and modulate hepcidin and ferroportin 
expression in response to elemental iron (Pinto et al, Immunology 130: 217-230, 2010) 
It is now an ambition of the group to move from the established evidence that lymphocytes can 
contribute to the regulation of iron metabolism, to the clarification of the mechanisms of how it happens. It is 
also our ambition to elucidate how CD8
+
 T lymphocyte numbers are regulated and maintained at stable 
homeostatic levels in the peripheral blood. The specific aims of the present project are therefore part of that 
larger general aim of the group. 
 
Motivations of the student 
To acquire skills in terms of scientific reasoning. 
To develop the competence of working with a research team with structured functions and 
responsibilities.  
To contact with laboratory techniques and with the dynamic between clinic and primary sciences in 
the scope of medicine. 
To get personal accomplishment. 
Pitfalls | Problemas 
As mentioned before, numerous studies correlated CD8+ T cells with presenting clinical picture, but 
it is still unclear what leads to these anomalies. No studies have addressed so far the issue of cell cycle in 
CD8+ lymphocytes from HH patients. 
Research questions | Questões a investigar 
What are the mechanisms that justify lower numbers of CD8+ T lymphocytes in peripheral blood 
from HH patients, as compared to healthy individuals? 
Are they related to different cell proliferation indexes and/or cell death by apoptosis? 
Working hypothesis | Hipóteses de trabalho 
Our general working hypothesis is that low numbers of CD8+ T lymphocytes, found in peripheral 
blood from HH patients, may be associated with alterations in cell cycle or progression of CD8+ T cells into 
apoptosis. 
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Aims | Objectivos 
The general aim of this project is to analyze if there are qualitative alterations on peripheral blood 
lymphocytes from HH patients, possible related to their numbers. 
Specifically, this research aims to analyze T lymphocytes from HH patients, homozygous for the 
mutation C282Y, and normal controls (all recruited at the Hematology Service of HSA), using cell cycle and 
apoptosis target components. 
Goals | Metas 
It is expected that the study of cell cycle and apoptosis in T cells contribute to the knowledge about 
variability in these population numbers, among HH patients. 
Implication | Implicações 
Considering the fact that lymphocyte counts have a consistent pattern of correlation with clinic of 
HH, the explanation of what is underlying abnormalities may lead us to a better comprehension of this 
heterogeneity. If anomalies are found, they might be implicated in the expression of the disease.  
Study design | Desenho do estudo 
Classification | Classificação 
Local: National and institutional study. 
Type: Analytic, observational, cross-sectional and case-control study. 
Nature: Clinical and laboratorial study. 
Universe, population and sample | Universo, população e amostra 
Universe | Universo 
Patients: HH patients homozygous for the C282Y mutation of the HFE gene.  
Controls: Healthy adult individuals.  
Population | População 
Patients: The population analyzed in this study will be composed by HH patients 
homozygous for the C282Y mutation of the HFE gene from the Hemochromatosis Clinic 
from HSA/CHP. A total of about  500 patients are registered and are regularly followed-up 
at the clinic, and 90 of these are genetically characterized as HH homozygous for the C282Y 
mutation, i.e., the population of interest for the present study.  
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Immunological characterization: The immunological characterization of patients 
included the number of peripheral blood CD8+ T lymphocytes. For the purpose of 
phenotypic characterization of patients, CD8+ T lymphocyte numbers were 
classified as “low” when they were  ≤0.41 × 106/ml and “high” when they were 
>0.41 × 10
6
/ml, as defined in previous studies of lymphocyte populations in 
Hemochromatosis (Cruz E et al, 2006a; Cruz E et al, 2004; Cruz E et al, 2006b). 
These cut-off values were based on the median values of the parameters previously 
established on a control population from the north of Portugal (Cruz E et al, 2006a).  
Controls: The control population for this project will be composed by the regular blood 
donors attending the HSA Blood Bank. 
Sample | Amostra 
Patients: The sample population will be composed by two groups of patients: a group of 15 
subjects with low numbers of CD8 + T lymphocytes, and another group of 15 subjects with 
high numbers of CD8 + T lymphocytes.   
Controls: The sample population for this project will be composed by a group of 15 subjects, 
selected among the population of regular blood donors attending the HSA Blood Bank. 
Participant selection | Selecção dos participantes 
Participants will be selected in a non-probabilistic consecutive way (by convenience).  
Patients and blood donors will be consecutively recruited at the time of their consultation and 
volunteer blood donation, respectively.  
Eligibility criteria | Critérios de elegibilidade 
Inclusion criteria: 
 To be followed at the Hemochromatosis Clinic, as a HH patient homozygous for the C282Y 
mutation of the HFE gene. 
 Have a scheduled consultation during the period of recruitment  
 Agree to participate in the project 
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Exclusion criteria: 
 Patients with clinical conditions known to influence total lymphocytes numbers (such as 
autoimmune or viral diseases) will be excluded. 
 Controls whose donation is the first will be excluded.  
Working plan | Plano de trabalho 
Tasks | Tarefas 
TASK 1: Inform about the study and ask to participate  
TASK 2: Data collection from clinical process  
TASK 3: Blood sample collection 
TASK 4: Analytical procedures  
TASK 5: Analysis and interpretation of results  
TASK 1 – Inform about the study and ask to participate 
- Duration:  
3 months 
- Starting and ending dates:  
01-10-2011 a 31-12-2011 
- Institutions, Departments and Services: 
HSA/CHP – DM – SHC – Consulta de Hemocromatose e Sector de Dadores de Sangue 
- Investigators:  
Maria João Silva; Graça Porto. 
- Aims:  
Inform the patients and blood donors about the goals and features of the study.  
Request their participation in the study, and signature of informed consent. 
- Description:  
Patients: During the period of consultation, the student (Maria João Silva) will be presented 
to the patients by the supervisor and responsible for the Hemochromatosis Clinic (Graça 
Porto), will inform them about the study, requesting their participation. If they agree to 
participate, they will have to sign the informed consent.  
Controls: On specific days in which the supervisor is responsible for the observation and 
selection of regular blood donors at the Blood Bank, the student will go to the department; 
the supervisor will present the student to the blood donors, and she will inform them about 
the study, requesting their participation. If they agree to participate, they will have to sign the 
informed consent.  
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- Functions and responsabilities: 
Investigators Functions and responsabilities 
Graça Porto Present the student to the patients /blood donors.   
Maria João Silva Inform the patients/blood donors about the study and request their participation.  
 
TASK 2 – Data collection from clinical files  
- Duration:  
3 months 
- Starting and ending dates:  
01-10-2011 a 31-12-2011 
- Institutions, Departments and Services: 
HSA/CHP – DM – SHC – Consulta de Hemocromatose 
- Investigators:  
Maria João Silva; Graça Porto. 
- Aims:  
Collect clinical data from patients and controls clinical files. 
- Description:  
During the period of consultation, according to the participant recruitment, it will be 
collected the corresponding analytic data registered at the moment of diagnosis in their 
clinical files; in the next week, will be collected the results from the CBC and biochemical 
study, which is normally made after regular phlebotomies.  
The collection of controls´ data will be held under the same rules. 
The list of analytic parameters is described in the form attached. The supervisor will 
overlook the process of data collection from clinical files.  
- Functions and responsabilities: 
Investigators Functions and responsabilities 
Maria João Silva Data collection and registering  
Graça Porto Supervision of data collection and registering 
 
TASK 3 – Blood sample collection  
- Duration:  
3 months 
- Starting and ending dates:  
01-10-2011 a 31-12-2011 
- Institutions, Departments and Services: 
HSA/CHP – DM – SHC – Consulta de Hemocromatose; Sector de Dadores de Sangue 
- Investigators:  
Nurse (Consulta de Hemocromatose) – Enf. Graça Melo. 
- Other collaborators:  
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Nurses (Dadores de Sangue, SHC, HSA/CHP). 
- Aims:  
Collect blood samples. 
- Description:  
It will be carried out the collection of 2 blood samples (1 tube with EDTA-K3, with 4.5ml of 
blood; 1 tube with sodic heparin with 7.5 ml of blood);  
The procedure does not involve risks, besides the implicated in any venous puncture; 
It will be collected at most 2 samples from patients and 2 samples from blood donors per 
week (1 sample of each, at each period of consultation);  
The blood samples will be sent to the LC (Laboratório de Citometria) SHC-HSA-CHP , 
addressed to Técn. Sónia Fonseca. 
- Functions and responsabilities: 
Investigators Functions and responsabilities 
Graça Melo Collect blood samples from patients 
Deliver the samples in LC 
Other nurses (Dadores de Sangue) Collect blood samples from blood donors 
Deliver the samples in LC   
 
TASK 4 – Analytical procedures  
- Duration:  
3 months 
- Starting and ending dates:  
01-10-2011 a 31-12-2012 
- Institutions, Departments and Services: 
HSA/CHP – DM – SHC – LC 
- Investigadores:  
Maria João Silva; Sónia Fonseca; Margarida Lima. 
- Aims:  
To quantify total of peripheral blood T-cells and CD4+ and CD8+ T cell populations; 
To quantify the percentage of peripheral blood CD8+ T cells, and of CD4+ T cells at the S 
and G2/M phases of the cell cycle; 
To quantify the percentage of apoptotic peripheral blood CD8+ T cells and of CD4+ T cells. 
- Description:  
The quantification of the CD4+ and CD8+ T cells populations, the CD8+ and CD4+ T 
lymphocytes cell cycle study, and the quantification of apoptotic CD8+ and CD4+ T 
lymphocytes will be performed by flow cytometry. 
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- Functions and responsabilities: 
Investigators Functions and responsabilities 
Sónia Fonseca Performance of the technique and analysis of results 
Maria João Silva Cooperation with the performance of the technique and analysis of results 
Margarida Lima Supervising of the study and analysis of results 
 
TASK 5 – Analysis and interpretation of results  
- Duration:  
2 months 
- Starting and ending dates:  
02-01-2012 a 30-03-2012 
- Institutions, Departments and Services: 
HSA/CHP – DM – SHC 
- Investigators:  
Maria João Silva; Graça Porto.  
- Aims:  
To study the relationship between CD8+ and CD4+ T cell numbers and their phenotypic 
profile (%S and G2/M cells and % of apoptotic cells). 
- Description:  
Data will be analyzed with the support of statistic software (SPSS or Statgraphics); 
Descriptive statistics: The mean, median and standard deviation of the percentage and 
absolute numbers of total T-cells, CD4+ T-cells and CD8+ T-cells and CD4/CD8 ratios;  
Inferential statistics: Association studies between CD8+ and CD4+ numbers and the 
corresponding phenotypic profile (%S and G2/M cells and % of apoptotic cells) will be 
performed. 
- Functions and responsabilities: 
Investigators Functions and responsabilities 
Graça Porto Supervision of analysis and interpretation of results 
Maria João Silva Analysis and interpretation of results  
 
Material and Methods | Material e Métodos 
Sample collection  | Colheita das amostras 
Blood samples will be obtained at the time of the patients and controls regular visits to the clinic and 
blood bank respectively. It is expected that at the time of the visit routine measurements of biochemical 
parameters of iron metabolism (serum iron, serum transferrin, transferrin saturation and serum ferritin) and 
CBC will be obtained. At this moment, the participants will be informed about the study and asked to give 
their Informed Consent.  
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Samples for T-cell immunophenotyping and cell cycle studies will be collected into K3-ethylene-
diamine-tetracetic acid (EDTA-K3)-containing tubes, whereas samples to be used in apoptosis studies will 
be collected into tubes containing sodium heparin. Overall, about 10 ml of blood will be collected. 
Sample processing | Processamento das amostras 
All technical procedures will be executed at the Flow Cytometry Lab (CHP – HSA – SHC) 
T cell immunophenotyping 
Rationale: Flow cytometry has become a standard laboratory tool in the identification of lymphocyte 
populations and subpopulations, a method referred to as immunophenotyping. The clinical application of this 
technology has been facilitated by the development of instruments and data analysis systems suitable for 
routine use in diagnostic laboratories. In addition, the expanded range of monoclonal antibodies (Mab) 
specific for lymphocyte surface antigens directly conjugated to a number of different fluorochromes are now 
available. By staining cells with Mab with different specificities conjugated with fluorochromes that emit 
light of different wavelengths it is possible to differentiate between different lymphocyte populations by 
staining cells in a single tube. For instance, anti-CD45 Mab stains all leukocytes with different intensity 
(lymphocytes have a high CD45 expression), anti-CD3 stains T cells and anti-CD4 and anti-CD8 Mab can be 
used to distinguish CD4+ and CD8+ T-cell populations. Some of the fluorochromes that are currently used in 
combination are the Fluorescein isothiocyanate (FITC, maximum emission ~520 nm, green fluorescence), 
Phycoerythrin (PE, maximum emission ~576 nm, orange fluorescence), the Phycoerythrin-Texas Red-X 
(ECD, maximum emission ~620 nm, red fluorescence) and the Phycoerythrin-Cy5 (PC5, maximum emission 
~670 nm, deep red fluorescence), all of each are excitable with the argon ion laser (488 nm light length 
emission) used in most benchtop cytometers. 
Flow cytometry protocol: The blood sample will be submitted to cell surface immunophenotyping 
with FITC-conjugated mouse anti-human CD45 (pan leukocyte antigen), RD-conjugated mouse anti-human 
CD4 (CD4-RD1) and ECD-conjugated mouse anti-human CD8 (CD8-ECD) and PC5-conjugated mouse 
anti-human CD3 (CD3-PC5) Mab (IgG) (CD45-FITC / CD4-RD1 / CD8-ECD / CD3-PC5), using a non-
wash whole blood direct immunofluorescence staining method. Erythrocyte lysis and leukocyte fixation will 
be performed with the Immunoprep Reagent System
TM
 (Beckman Coulter, BC), which contains reagents to 
lyse the red blood cells (Reagent A), to stop the lysing process (Reagent B) and to fix the cells (Reagent C),  
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using an automated sample preparation station (TQ-prep
TM, BC), following the manufactures’ instructions. 
Stained samples will be acquired in a flow cytometer (EPICS-XL-MCL
TM
, BC) using the System II
TM
 
software (BC).  
Flow cytometry data analysis: Stored listmode data will be analyzed using the System II
 TM
 Software 
(BC). The percentage of total T cells (low SSC signal, CD45+high, CD3+ cells) among lymphocytes and the 
percentage of CD4+ (low SSC signal, CD45+high, CD3+CD4+ cells) and CD8+ (low SSC signal, 
CD45+high, CD3+CD8+ cells) T cells among total T cells and among lymphocytes will be calculated.  
Distribution of CD8+ and CD4+ T cells throughout the cell cycle phases 
Rationale: The DNA measurement and cell cycle studies will be performed by flow cytometry, based 
upon the ability of propidium iodide (PI) to bind stoichiometrically to double strand DNA under appropriate 
staining conditions. Cells stained in this manner will emit red fluorescence in direct proportion to their DNA 
content and based on this parameter the percentage of cells in G0+G1 (DNA content = n), S and G2+M 
(DNA content = 2n) phases of the cell cycle will be evaluated. In order to determine the DNA content in 
specific lymphocyte populations, blood cells will be stained for cell surface molecules prior to DNA staining 
with PI. This will be done by staining cells with a FITC-conjugated mouse anti-human CD8 or CD4 Mab 
(green fluorescence), following by staining with a FITC-conjugated rabbit anti-mouse IgG polyclonal 
antibody (Ab) 
Flow cytometry protocol: The blood sample will be submitted to cell surface immunophenotyping 
with FITC-conjugated mouse anti-CD4 or anti-CD8 Mab (IgG) followed by staining with FITC conjugated 
rabbit anti-mouse IgG polyclonal Ab and basic cellular DNA measurement based on flow cytometry 
techniques, using the COULTER DNA PREP Reagents Kit
TM
, according to a protocol that was described in 
detail (Lima M et al, 2000). This reagent kit contains non-ionic detergents to permeabilizing cells (DNA 
PREP LPR reagent), PI (to stain double strain nucleic acids, DNA and dsRNA) and RNAse (to destroy 
RNA) (DNA PREP Stain reagent). After staining, samples will be acquired in a flow cytometer (EPICS-XL-
MCL, BC) using the System II
TM
 software (BC).  
Flow cytometry data analysis:  Stored listmode data will be analyzed using specific software for 
DNA analysis “Multicyle for WindowsTM” (Phoenix Flow System, PFS). Using this software, the percentage 
of CD8+ T-cells and CD4+ T-cells in each phase of the cell cycle (G0+G1, S and G2M) will be calculated. 
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Detection of apoptotic of T cells  
Rationale: Annexin V is a protein that binds phospholipids in the presence of calcium, which has a 
high affinity for phosphatidylserine (PS), a negatively charged phospholipids located in the inner leaflet of 
the plasma membrane of the viable cells. PS is exposed at the cell surface early during the apoptotic process 
and externalization of PS on the cell surface allows cells to bind Annexin V. The loss of membrane integrity 
accompanies the latest stages of cell death resulting from either apoptosis or necrosis and this phenomenon 
brings cells permeable to some dyes such as PI and 7-Amino-Actinomycin D (7-AAD). Thus, the intact 
membranes viable cells do not stain with Annexin V and exclude PI and 7-AAD, whereas the membranes of 
dead and damaged cells stain with Annexin V and are permeable to PI and 7-AAD. In addition, apoptotic 
cells stains with Annexin V and exclude PI and 7-AAD. Therefore, staining with FITC or PE conjugated 
Annexin V is typically used in conjunction with PI or 7-AAD, respectively, to allow the identification and 
quantification of viable (Annexin V negative and PI / 7-AAD negative), early apoptotic (Annexin V positive 
and PI / 7-AAD negative) and dead (Annexin V positive and PI / 7-AAD positive). This assay does not 
distinguish between cells that have undergone apoptotic death versus those that have died as a result of a 
necrotic pathway because in both cases, the dead cells will stain with Annexin and PI / 7-AAD.  
Flow cytometry protocol: Apoptotic T cells will be assessed through flow cytometry, using the 
Annexin V-FITC/7-AAD Kit ® (BC), containing FITC conjugated Annexin V, 7-AAD staining solution and 
Annexin V binding buffer. Samples will be acquired in a flow cytometer (EPICS-XL-MCL
 TM
, BC) using the 
System II
 TM
 software (BC). 
Flow cytometry data analysis: Stored listmode data will be analyzed using the System II
 TM
 software 
(BC). The percentage of viable (Annexin V negative / 7-AAD negative), early apoptotic (Annexin V positive 
/ 7-AAD negative) and late apoptotic or already dead (Annexin V positive / 7-AAD positive) CD8+ T-cells 
will be calculated.  
Data analysis | Análise dos dados 
Association studies between CD8+ and CD4+ T lymphocytes numbers and the corresponding 
phenotypic profile (%S and G2/M cells and % of apoptotic cells) will be performed. Data will be further 
correlated with the other clinical parameters (CBC and biochemical). 
Data will be analyzed with the support of statistic software (SPSS or Statgraphics). 
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Equipment, material e reagents | Equipamento, material e reagentes 
Equipment | Equipamento 
It will be used the equipment available at the LC of SHC-HSA-CHP.  
 
Laboratory Equipment Automated hematologic counters: Coulter LH 780 (BC) 
 Flow cytometers: EPICS-XL-MCL
TM
 (BC) 
 Sample preparation stations: TQ-PreP
TM
 workstation (BC) 
 Refrigerators 
 Centrifuges 
 Automated Micropipetes 
Hardware Computers and Printers 
Software System II
TM
 (BC); Multicycle for Windows
TM
 (PFS) 
BC, Beckman Coulter; PFS (Phoenix Flow Systems) 
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Reagents | Reagentes 
Finality Description Manufactore Reference Distributor 
Sample collection EDTA (K3) BDB - Enzifarma 
Heparin (sodium) BDB - Enzifarma 
Flow 
cytometric 
studies 
Cell preparation (washing 
and suspension) 
Phosphate Buffer Saline 
(PBS) buffer 
BC 6603369 IZASA 
T cell 
immunophenotyping 
Mouse anti-human CD45-
FITC / CD4-RD1 / CD8-
ECD / CD3-PC5 
BC-IOT 6607013 IZASA 
Immunoprep
TM
 reagent 
system 
BC 7546946 IZASA 
Cell cycle studies DNAprep
TM
 reagent system BC 6607055 IZASA 
Mouse anti-human CD4 
FITC 
BC-IOT A07750 IZASA 
Mouse anti-human CD8 
FITC 
BC-IOT A07756 IZASA 
Rabbit anti-mouse IgG 
FITC 
DK F0232 Lusopalex 
Apoptosis studies Annexin V-FITC/7-AAD 
Kit 
BC-IOT IM3614 IZASA 
Mouse anti-human anti-
CD8 ECD 
BC 737659 IZASA 
BD, Becton Dickinson; BC, Beckman Coulter; DK, Dako; IOT, Immunotech 
Material consumível | Consumable material 
5 ml polypropylene tubes; Pasteur pipettes; Pipette tips 
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Calendarization | Calendarização 
 
Duration | Duração 
Global: 22 months   Execution: 6 months 
 
Start and end dates | Datas de início e conclusão 
Global: October 2011 - July 2012 Execution: October 2011 a March 2012 
 
Chronogram | Cronograma 
YEAR 2010 2011 2012 
Month 10 11 12 01 02 03 04 05 06 07 08 09 10 11 12 01 02 03 04 05 06 07 
Choice of theme and 
subject 
x                      
Identification of 
problems/issues 
 x                     
Review / study design x x x x x x                 
Preparation of project 
proposal 
  x x x x x                
Submission for approval        x               
Presentation of the 
proposal 
        x x             
Project implementation             x x x x x x     
Sample collection and 
analytical procedures 
            x x x        
Analysis and 
interpretation of results 
               x x x     
Report writing                   x x   
Presentation of  the 
results 
                    x x 
Thesis defense                      x 
 
Output indicators | Indicadores de produção 
Oral communications and posters | Comunicações orais e posters 
 Oral presentation of the proposal at the 3th JIIC (Jornadas de Iniciação á Investigação Clínica 
(June / July 2011)   
 Oral presentation of the results at the 4th JIIC (June / July 2012) 
 Presentation of the results in poster in scientific meeting of the specialty (ex. Sociedade 
Portuguesa de Imunologia) (2012) 
Manuscripts | Trabalhos escritos 
 Research Project proposal (2011) 
 Thesis defense (2012) 
 Article for publication in national or international medical journal with referees (2012) 
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FINANTIAL PLAN | PLANO FINANCEIRO 
Budget | Orçamento 
All the analysis will be executed at LC (SHC-HSA-CHP), with reagents purchased using funds made 
available by ICBAS, and the analysis will be carried out after working hours. 
 
 Price (€) 
Reagents and other consumables (*) 7117,52 
Poster (impression) 50,00 
Congress (inscription) 200,00 
Jornadas de Iniciação à Investigação Clínica (JIIC) (organization) 50,00 
TOTAL 7417,52 
(*) Described in detail in the next page 
Funding | Financiamento 
This study will be financed by ICBAS/UP. 
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Reagents and other consumables 
Finalidade Description Manufacture Reference Distributor Price / Units 
(€) 
Units Price  
(€) 
Sample collection EDTA-K3 containing tubes BD - Enzifarma ~100,00 45 
(45 samples) 
100,00 
Heparin containing tubes BD - Enzifarma ~100,00 45 
(45 samples) 
100,00 
Flow 
cytometry 
Cell preparation Phosphate Buffer Saline (PBS) buffer BC 6603369 IZASA 55,35 1  
(15 packets, 15 
liters) 
55,35 
T cell 
immunophenotyping 
Mouse anti-human CD45-FITC / CD4-RD1 / 
CD8-ECD / CD3-PC5 
BC-IOT 6607013 IZASA 1469,85 1 vial  
(50 tests) 
1469,85 
Immunoprep
TM
 reagent system BC 7546946 IZASA 565,80 1 vial 
(100 tests) 
565,80 
Cell cycle studies DNAprep
TM
 reagent system BC 6607055 IZASA 1088,55 1 vial 
(100 tests) 
1088,55 
Mouse anti-human CD4 FITC BC-IOT A07750 IZASA 590,40 1 vial 
(100 tests) 
590,40 
Mouse anti-human CD8 FITC BC-IOT A07756 IZASA 590,40 1 vial 
(100 tests) 
590,40 
Rabbit anti-mouse IgG FITC DK F0232 Lusopalex 429,27 1 vial 
(100 tests) 
429,27 
Apoptosis studies Annexin V-FITC/7-AAD Kit BC-IOT IM3614 IZASA 1543,65 1 vial 
(100 tests) 
1543,65 
Mouse anti-human anti-CD8 ECD BC 737659 IZASA 584,25 1 vial 
(100 tests) 
584,25 
TOTAL 7117,52 
BD, Becton Dickinson; BC, Beckman Coulter; DK, Dako; IOT, Immunotech 
Polypropylene tubes, Pasteur pipettes, and pipette tips will be provided by the Lab. 
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GLOSSARY | GLOSSÁRIO 
Abreviations and acronims | Abreviaturas e acrónimos 
7-AAD, 7-Amino-Actinomycin D 
BC, Beckman Coulter 
BD, Becton Dickinson 
BCRIB, Basic and Clinical Research on Iron Biology 
CHP, Centro Hospitalar do Porto 
CBC, Complete Blood Count 
DIIC, Disciplina de Iniciação à Investigação Clínica 
DK, Dako 
DM, Departamento de Medicina do HSA/CHP 
DNA, Deoxyribonucleic acid 
ECD, Phycoerythrin-Texas Red-X (maximum emission ~620 nm, red fluorescence) 
EDTA, Ethylene-diamine-tetracetic acid 
FITC, Fluorescein isothiocyanate (maximum emission ~520 nm, green fluorescence) 
HH, Hemocromatose Hereditária 
HSA, Hospital de Santo António 
IBMC, Instituto de Biologia Molecular e Celular 
ICBAS, Instituto de Ciências Biomédicas Abel Salazar 
IOT, Immunotech 
IS, Immune system 
JIIC, Jornadas de Iniciação à Investigação Clínica 
LC, Laboratório de Citometria do HSA/CHP 
MIM, Mestrado Integrado em Medicina 
PBS, Phosphate buffered saline 
PC5, Phycoerythrin-Cy5 (maximum emission ~670 nm, deep red fluorescence), 
PE, Phycoerythrin (maximum emission ~576 nm, orange fluorescence) 
PI, Propidium iodide (Iodeto de propideo) 
PS, Phosphatidylserine 
SHC, Serviço de Hematologia Clínica do HSA/CHP 
UP, Universidade do Porto 
 
Technical terms | Termos técnicos 
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ANNEXES | ANEXOS 
- Formulários de recolha de dados clínicos e laboratoriais 
- Termos de consentimento informado (doentes e dadores de sangue) 
- Folhetos informativos (doentes e dadores de sangue) 
- Folha de rosto de estudo de investigação 
- Pedidos de autorização 
- Termos de responsabilidade 
- Autorizações locais 
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 Formulário de recolha de dados 
 
Nome  
 Nº do processo  Data nascimento  
 
 
Avaliação hematológica Data diagnóstico Data actual 
Hemoglobina   
Leucócitos   
Neutrófilos   
Linfócitos   
Monócitos   
 
Avaliação bioquímica                
Ferro sérico   
Transferrina   
Saturação de Transferrina 
Ferritina Sérica 
  
  
 
Avaliação imunológica 
Linfócitos T CD4 (%linfo)   
Linfócitos T CD8 (%linfo)   
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Termo de consentimento informado (Doentes) 
 
O ciclo celular e a apoptose de linfócitos T de doentes com hemocromatose hereditária 
 
Eu, abaixo-assinado__________________________________________________________: 
 
Fui informado de que o estudo de investigação acima mencionado se destina a estudar a 
Hemocromatose Hereditária, uma doença que se caracteriza pela acumulação de ferro no organismo. Os 
doentes com Hemocromatose Hereditária têm com frequência uma diminuição dos linfócitos T CD8 no 
sangue e essa diminuição parece ter relação com a acumulação de ferro. Neste estudo pretendemos estudar os 
mecanismos que conduzem à diminuição dos linfócitos T CD8 e para isso é necessário analisar os dados 
clínicos e fazer algumas análises ao sangue. 
Sei que neste estudo está prevista a colheita de dados do processo clínico e a colheita de uma 
amostra de sangue vai ser utilizada para fazer análises. 
Foi-me garantido que todos os dados relativos à identificação dos Participantes neste estudo são 
confidenciais. 
Foi-me garantido que o sangue colhido não será utilizado para a realização estudos genéticos.  
Sei que posso recusar-me a participar ou interromper a qualquer momento a participação no 
estudo, sem nenhum tipo de penalização por este facto. 
 
Compreendi a informação que me foi dada, tive oportunidade de fazer perguntas e as minhas dúvidas 
foram esclarecidas. 
 
Aceito participar de livre vontade no estudo acima mencionado. 
Concordo que seja efetuada a colheita de duas amostras de sangue para realizar as análises que 
fazem parte deste estudo. 
Também autorizo a divulgação dos resultados obtidos no meio científico, garantindo o anonimato. 
 
Nome do Participante no estudo. 
 
 
 
Data:___/___/______         Assinatura 
  
 
 
Nome da Aluna: 
 
 
Data:___/___/______         Assinatura 
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Termo de consentimento informado (Dadores de sangue) 
 
O ciclo celular e a apoptose de linfócitos T de doentes com hemocromatose hereditária 
 
Eu, abaixo-assinado__________________________________________________________, 
 
Fui informado de que o estudo de investigação acima mencionado se destina a estudar a 
Hemocromatose Hereditária, uma doença que se caracteriza pela acumulação de ferro no organismo e em 
que há com frequência uma diminuição dos linfócitos T CD8 no sangue, que parece ter relação com a 
acumulação de ferro. Neste estudo pretende-se estudar os mecanismos que conduzem à diminuição dos 
linfócitos T CD8 através de algumas análises ao sangue e para isso são necessárias amostras de sangue de 
pessoas saudáveis. 
Foi-me garantido que todos os dados relativos à identificação dos Participantes neste estudo são 
confidenciais. 
Foi-me garantido que o sangue colhido não será utilizado para a realização estudos genéticos.  
Sei que posso recusar-me a participar ou interromper a qualquer momento a participação no 
estudo, sem nenhum tipo de penalização por este facto. 
 
Compreendi a informação que me foi dada, tive oportunidade de fazer perguntas e as minhas dúvidas 
foram esclarecidas. 
 
Aceito participar de livre vontade no estudo acima mencionado. 
Concordo que seja efetuada a colheita de duas amostras de sangue para realizar as análises que 
fazem parte deste estudo. 
Também autorizo a divulgação dos resultados obtidos no meio científico, garantindo o anonimato. 
 
Nome do Participante no estudo. 
 
 
 
Data ___/___/_____         Assinatura 
  
 
 
 Nome da Aluna. 
 
 
 
Data ___/___/_____         Assinatura 
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O ciclo celular e a apoptose de linfócitos T de doentes com 
hemocromatose hereditária 
Folheto informativo (Doentes) 
A Hemocromatose Hereditária é uma doença que se caracteriza pela 
acumulação de ferro nos órgãos.  
Os doentes com Hemocromatose Hereditária tem uma diminuição dos 
linfócitos T CD8+ no sangue e essa diminuição parece ter relação com a 
acumulação de ferro. 
Neste estudo vamos investigar os mecanismos que conduzem a uma 
diminuição dos linfócitos T CD8 no sangue. 
Para isso, precisamos de estudar doentes com Hemocromatose e por 
isso estamos a pedir a sua colaboração. 
Se concordar em participar, será consultado o seu processo clínico e 
serão colhidas duas amostras de sangue para fazer algumas análises. 
O sangue colhido não será utilizado para estudos genéticos.  
Contamos com a sua participação. 
 
 
Muito obrigada! 
 
 
 
Maria João Silva 
DIIC, Mestrado Integrado em Medicina – ICBAS/UP 
O ciclo celular e a apoptose de linfócitos T de doentes com 
hemocromatose hereditária 
Folheto informativo (Dadores de Sangue) 
A Hemocromatose Hereditária é uma doença que se caracteriza pela 
acumulação de ferro nos órgãos.  
Os doentes com Hemocromatose Hereditária tem uma diminuição dos 
linfócitos T CD8+ no sangue e essa diminuição parece ter relação com a 
acumulação de ferro. 
Neste estudo vamos investigar os mecanismos que conduzem a uma 
diminuição dos linfócitos T CD8 no sangue. 
Para isso, precisamos de amostras de sangue de pessoas normais e por 
isso estamos a pedir a sua colaboração. 
Se concordar em participar, serão colhidas duas amostras de sangue 
para fazer as análises que fazem parte deste estudo. 
O sangue colhido não será utilizado para estudos genéticos.  
Contamos com a sua participação. 
 
 
Muito obrigada! 
 
 
Maria João Silva 
DIIC, Mestrado Integrado em Medicina – ICBAS/UP 
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The project here reported, previously approved by Centro Hospitalar do Porto, was executed between 
7
th
 November of 2011 and 30
th
 April of 2012. It was held in Clinical Hematology Service (Hemochromatosis 
Clinic and Cytometry Laboratory), and involved the cooperation of all the collaborators previously 
mentioned. The general aim of the project was to analyse T lymphocytes from Hereditary Hemochromatosis 
(HH) patients, homozygous for the mutation C282Y, and normal controls, using cell cycle and apoptosis 
target components, and verify if there are qualitative alterations on peripheral blood lymphocytes from HH 
patients, possibly related to their numbers. 
Following the project proposal, where the background and objectives of the work were explained in 
more detail, this report describes the population studied, the procedures executed, the results obtained and 
respective discussion.  
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DESIGN AND METHODS  
Patients 
The study population consisted of 20 patients with HH (13 males and 7 females, with a median age 
of 52 years, ranging from 23 to 74 years). These included 10 individuals classified with the immunological 
phenotype of “low CD8+ T cells” (50%) and 10 individuals classified with the immunological phenotype of  
“high CD8+ T cells” (50%). 
All patients were diagnosed and are regularly followed-up at the Hemochromatosis Outpatient Clinic 
of Hospital de Santo António, Porto, where all the clinical information is recorded. Only patients genetically 
characterized as homozygous for the C282Y mutation of HFE were included. Clinical and genetic data from 
these patients have been published previously (Porto G et al, 1997; Porto G et al, 2001; Cardoso C et al, 
2001).  
During the study period, patients were evaluated at different stages of their treatment course. Four 
patients were under intensive phlebotomy treatment, and the remaining 16 were receiving maintenance 
therapy. The inclusion of patients at different stages of iron load was important in order to allow an analysis 
of cell cycle parameters in relation to a wide range of TfSat values. 
All clinical material was collected and stored with the informed consent of the patients according to 
the approval of the Ethical Committee of Hospital Santo António, Porto. 
Controls 
The control population was randomly recruited from the population of regular blood donors of the 
Hospital de Santo António, Porto and consisted of 13 individuals (9 males and 4 females with a median age 
of 47 years, ranging from 26 to 64 years). From the initial sample collected, one individual was excluded 
because of an atypical pattern of entrainment on flow cytometry analysis. Thus, the final sample consisted of 
12 individuals, 8 males and 4 females, with a median age of 45 years, ranging from 26 to 64 years. 
Homozygosity for the C282Y allele was assumed to be negative through the biochemical analysis of iron 
status. Informed consent for the study was also obtained from all recruited subjects according to the approval 
of the Ethical Committee of Hospital Santo António, Porto. 
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Sample collection 
Blood samples were obtained at the time of the patients and controls regular visits to the clinic and 
blood bank respectively. Samples for T-cell immunophenotyping and cell cycle studies were collected into 
K3-ethylene-diamine-tetracetic acid (EDTA-K3)-containing tubes, whereas samples to be used in apoptosis 
studies were collected into tubes containing sodium heparin.  
Experimental Procedure 
All technical procedures were executed at the Flow Cytometry Lab (Department of Haematology, 
Hospital de Santo António Porto). 
 
T cell immunophenotyping 
 
Flow cytometry protocol: The blood sample was submitted to cell surface immunophenotyping with 
fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD45pan leukocyte antigen, R-
phycoerythrin (R-PE, also known as RD1) -conjugated  mouse anti-human CD4 and phycoerythrin-Texas 
Red (PE-Texas Red, also known as ECD)-conjugated mouse anti-human CD8 and 
phycoerythrocyanin5(PC5)-conjugated mouse anti-human CD3 monoclonal antibodies (mAb) (CD45-FITC / 
CD4-RD1 / CD8-ECD / CD3-PC5) (Beckman Coulter, BC), using a non-wash whole blood direct 
immunofluorescence staining method. Erythrocyte lysis and leukocyte fixation was performed in the TQ-
prep
TM
 automated sample preparation station (BC), using the Immunoprep Reagent System
TM
 (BC), which 
contains reagents to lyse the red blood cells (Reagent A), to stop the lysing process (Reagent B) and to fix 
leukocytes (Reagent C), following the manufactures’ instructions. Stained samples were acquired in an 
EPICS-XL-MCL
TM
 flow cytometer (BC), using the System II
TM
 software (BC).  
 
Flow cytometry data analysis: Stored listmode data were analyzed using the System II
 TM
 Software 
(BC). The percentage of total T cells (low SSC signal, CD45+high, CD3+ cells) among lymphocytes and the 
percentage of CD4+ (low SSC signal, CD45+high, CD3+CD4+ cells) and CD8+ (low SSC signal, 
CD45+high, CD3+CD8+ cells) T cells among total T-cells and among lymphocytes was calculated. 
 
Detection of apoptotic of T cells 
 
Flow cytometry protocol: Apoptotic T cells were assessed through flow cytometry, using the 
Annexin V-FITC/7-AAD Kit ® (BC), containing FITC conjugated Annexin V, 7-AAD staining solution and 
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Annexin V binding buffer, following the instructions of the manufactory. Apoptosis studies were performed 
on mononuclear peripheral blood cells separated by centrifugation on the Lymphoprep
TM
1.077 g/ml density 
gradient (NycomedPharma AS, Oslo, Norway), washed and suspended in RMPI culture medium, and kept 
overnight in the refrigerator before further processing. Samples were acquired in a flow cytometer (EPICS-
XL-MCL
 TM
, BC) using the System II
 TM
 software (BC). 
 
Flow cytometry data analysis: Stored listmode data was analyzed using the System II
 TM
 software 
(BC). The percentage of viable (Annexin V negative / 7-AAD negative), early apoptotic (Annexin V positive 
/ 7-AAD negative) and late apoptotic or already dead (Annexin V positive / 7-AAD positive) CD8+ and 
CD4+ T-cells was calculated.  
 
Distribution of CD8+ and CD4+ T cells throughout the cell cycle phases 
 
Flow cytometry protocol: The blood sample was submitted to cell surface immunophenotyping with 
FITC-conjugated mouse anti-CD4 or anti-CD8 IgGmAb followed by staining with FITC conjugated rabbit 
anti-mouse IgG polyclonal Ab and basic cellular DNA measurement based on flow cytometry techniques, 
using the DNA PREP Reagents Kit
TM
 (BC) according to a protocol that was described in detail (Lima M et 
al, 2000). This reagent kit contains non-ionic detergents to permeabilizing cells (DNA PREP LPR reagent), 
PI (to stain double strain nucleic acids, DNA and dsRNA) and RNAse (to destroy RNA) (DNA PREP Stain 
reagent). After staining, samples were acquired in an EPICS-XL-MCL flow cytometer (BC) using the 
System II
TM
 software (BC).  
 
Flow cytometry data analysis:  Stored listmode data were analyzed using specific software for DNA 
analysis “Multicyle for WindowsTM” (Phoenix Flow System, PFS). Using this software, the percentages of 
CD8+ and CD4+ T-cells in each phase of the cell cycle (G0/G1, S and G2/M) were calculated. 
Other laboratory studies 
Other laboratory studies for all subjects included a complete blood cell count and biochemical 
parameters of iron status, including the measurement of serum iron (Fe), ferritin, transferrin (Tf) and 
transferrin saturation (TfSat). 
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Statistical analysis 
Correlations between variables were analysed by simple linear regression. Differences in group 
means or sample distributions were tested respectively by the Student’s t-test and the Kolmogorov-Smirnov 
(KS) two sample test. For the purpose of analysis, logarithmic transformation was applied to the values of 
serum ferritin, since these have a logarithmic distribution. The p value of 0.05 was taken as the level of 
statistical significance. 
Data were analyzed by StatGraphics software (Statgraphics Statistical Graphics System, version 
16.0). 
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RESULTS   
Analysis of Apoptosis 
 
Overall comparisons between CD4+ and CD8+ T Cells (Figure 1) 
 
In general, a highly significant difference was found in the percentage of apoptotic cells between the 
CD4+ and CD8+ T lymphocyte subpopulations (T Test p=9,4x10
-8
, KS Test p=0,000002), the average 
apoptosis percentage being 21,8% ±9,9% in CD4+ T cells, and 47,3% ±21,8% in CD8+ T cells. 
Apoptosis in CD4+ T cells and CD8+ T cells was not influenced by gender but it was influenced by 
age in CD8+ T cells (R
2
=13,5%, r=0,37, p=0,0380), not in CD4+ T cells.   
 
HH patients vs. controls 
 
In general, apoptosis in CD4+ or CD8+ T cells was not statistically different between the groups of 
controls and HH patients and, in these, it was not influenced by the therapy stage (intensive vs. 
maintenance). In terms of association with T lymphocyte numbers, also no significant correlation was found 
between apoptosis and either CD4+ T or CD8+ cell counts (cells/mm3) in both HH patients and controls.  
 
Correlation with iron parameters  
 
Regarding the iron metabolism parameters, an overall significant correlation was found between the 
percentage of apoptosis in both CD4+ and CD8+ T cells and serum iron (respectively p=0,0359 and 
p=0,0353) and also transferrin saturation (respectively p=0,0316 and p=0,0205). Results of the respective 
correlation coefficients and Rsquare values are summarized in Table 1. No significant correlation was found, 
in general, with serum ferritin or transferrin. 
Cells in Apoptosis (%)
0 20 40 60 80 10 0
CD4+ T Cells
CD8+ T Cells
Figure 1. Comparison of apoptosis in CD4+ and CD8+ T cells population. 
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When considering the HH patients population alone, the correlations between, apoptosis and serum 
iron and transferrin saturation was even more striking in both CD4+ and CD8+ T cells. These results are 
illustrated in Figure 2. Moreover, in the case of HH patients, a significant correlation was also found between 
the log of ferritin and the percentage of apoptosis in both CD4+ and CD8+ T cells (respectively R
2
=20,5%, 
r=0,452, p=0,0452 and R
2
=22,7%, r=0,476, p=0,0339).  
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r=0,37 
R
2
=13,9% 
p=0,0359 
r=0,37 
R
2
=13,9% 
p=0,0353 
SatTf (%) 
r=0,38 
R
2
=14,5% 
p=0,0316 
r=0,41 
R
2
=16,6% 
p=0,0205 
Log 
Ferritin 
(ng/mL) 
N.S. N.S. 
 
Table1. Overall correlations between apoptosis in CD4+ and CD8+ T cells populations and iron parameters. N.S.- 
Not significant. S.L.R. – Simple linear regression. 
 
 
 
 
In face of the observation that iron parameters influence the percentage of apoptotic cells, we further 
analyzed the HH patients population in comparison to controls according to TfSat values, i.e., after dividing 
Figure 2. Correlation between apoptosis in CD8+ and CD4+ T cells, and transferrin saturation and serum iron in 
HH patients. 
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HH patients in two groups with TfSat above or below 50%. The only significant difference found was in the 
average apoptosis in CD8+ T cells between HH patients with TfSat<50% or ≥50% (p=0,028), but none of 
these groups was statistically different from controls who showed average values at an intermediate value 
between patients with low or high TfSat (respectively 49,8%±26,4%, 35,8%±8,6% and 56,3%±23,0% in 
controls, HH patients with TfSat< 50%and HH patients with TfSat≥50%). 
Distribution of CD8+ and CD4+ T cells throughout the cell cycle phases 
 
Overall comparison of CD4+ vs. CD8+ T Cells (Figure 3) 
 
The overall proportions of cells along the 3 phases of cells cycle was also highly significantly 
different between the populations of CD4+ and CD8+ T cells.  On average, 99,5% ±0,30% of CD4+ T cells 
vs. 98,4% ±1,56% of CD8+ T cells (T test p=0,00023, KS p=0,00067) were in phase G0/G1, while 0,431% 
±0,219% of CD4+ T cells and 1,218% ±1,063% of CD8+ T cells (T test p=0,0001, KS p=0,00067) were in 
phase S of the cell cycle, and 0,068% ±0,1186% of CD4+ T cells and 0,381% ±0,630% of CD8+ T cells (T 
test p=0,0079, KS p=0,000002) were in phase G2/M phase of the cell cycle. 
The percentages of both CD4+ and CD8+ T cells in each phase of cell cycle were not related to age 
or sex except for the percentage of CD4+ T cells in G2/M phase which was found higher in females 
(p=0,0159). There was no correlation between percentage of CD4+ T cells in each cell cycle phase and 
CD4+ T cells counts (cells/mm3), nor between the percentages of CD8+ T cells in each cell cycle phase and  
 
Figure 3.  Comparison of percentage of cells in G0/G1, G2/M and S phases of cell cycle in CD4+ and CD8+ T 
cells population. 
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the CD8+ T cells counts (cells/mm3). There was also no correlation between any of the iron parameters and 
the percentages of CD4+ or CD8+ T cells in different phases of cell cycle. 
 
 
HH patients vs. Control population 
 
In contrast to the results observed for apoptosis, in the case of cell cycle analyses, some differences 
could be observed between HH patients and controls. Average values of the percentages of CD4+ and CD8+ 
T lymphocytes in the different cell cycle phases are summarized in Table 2 where results are compared 
between patients and controls. In general, there were more lymphocytes (both CD4+ and CD8+) in S and 
G2/M, and less in G0/G1 phase in HH patients than in controls. These differences, however, reached only a 
statistical significance in G2/M (for both CD4+ and CD8+) and in G0/G1 for CD4+ cells only. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Comparison between % of CD4+ and CD8+ T cells in each cell cycle phases between controls and HH 
patients.  
 
A significant correlation between percentages of cells in each cell cycle phases and apoptosis was 
not observed in this study.  
 
 
 
 
 
 
 Controls HH Patients 
C
el
l 
C
y
cl
e 
P
h
as
es
 
% G0G1 CD4+ T Cells 
99,7% ±0,16% 99,4% ±0,35% 
T test p=0,0256 KS p=0,0281 
% G0G1 CD8+ T Cells 
98,9% ±1,25% 98,1% ±1,69% 
N.S. 
% G2M CD4+ T Cells 
0,008% ±0,029% 0,105% ±0,136% 
T Test p=0,0217 KS p=0,0000067 
% G2M CD8+ T Cells 
0,2% ±0,357% 0,49% ±0,735% 
 KS p=0,0025 
% S CD4+ T Cells 
0,342% ±0,162% 0,485% ±0,235% 
N.S. 
% S CD8+ T Cells 
0,942% ±1,00% 1,385% ±1,089% 
N.S. 
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DISCUSSION  
 
The present study was motivated by the search of a putative mechanism to explain the systematic 
finding of abnormally low CD8+ T lymphocytes in HH patients homozygous for the C282Y mutation in 
HFE (Porto G et al, 2007). To the best of our knowledge, this is the first study reporting the profile of 
peripheral blood lymphocytes in HH patients in terms of their percentages of apoptotic cells and their 
distribution in the different cell cycle phases. Although the results did not show any strong evidence that 
abnormalities in apoptosis or cell cycle progression could explain the abnormalities in CD8+ T cell numbers 
in these patients, they brought into light some new interesting aspects of lymphocyte biology and iron 
overload with potential fundamental and clinical relevance.  
The first result to highlight in this study is the clear demonstration of  marked differences in 
apoptosis and cell cycle progression between the subpopulations of CD4+ and CD8+ T lymphocytes, 
Although a higher percentage of apoptotic cells among the CD8+ subpopulation has been already observed 
in previously published studies of apoptosis in humans in the context of sepsis and pulmonary disease, this 
result has never been a focus of discussion or properly addressed in any of those studies (J. S. Nielsen et al, 
2011; Sung Chul Lim, et al 2011). In our view, this is a relevant finding that deserves fully consideration in 
future studies of lymphocyte activation and proliferation in the clinical setting. 
The second interesting finding in this study was the novel observation of a significant correlation 
between apoptosis and systemic iron parameters. Iron is essential for proper cell function, synthesis and 
division, but an excess of Fe
2+
 can cause the generation of reactive oxygen species which will provoke 
oxidative cell damage (N. Bresgen et al. 2010). Iron induced apoptosis is a reported phenomenon in human 
hepatocytes, rat neurons, but has never been described in human lymphocytes (N. Bresgen et al. 2007; 
Saadeldien HM et al. 2012). In this study, we found an interesting relationship between iron parameters and 
apoptosis in lymphocytes from the HH patient’s population, this association being more striking between 
TfSat values, and the CD8+ T cells. It should be stressed here that all previously described abnormalities in 
lymphocyte populations in HH were systematically found in the sub-population of CD8+T lymphocytes 
(Porto G et al, 2007). It could therefore be tempting to speculate that iron overload would contribute to 
decreased numbers of those cells in HH patients. However, a direct relationship between apoptosis and cell 
numbers was not found in the present study. A possible explanation for the lack of correlation of apoptosis 
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with the cell numbers could be the occurrence of compensatory mechanisms of cell proliferation in the 
context of increased apoptosis. The results on cell cycle markers may support that notion. The fact that HH 
patients had less resting cells and more cells in G2/M and S could be consistent with the hypothesis of a 
“more dynamic” pool of lymphocytes. To illustrate this notion we present in Figure 4 a summary of the 
comparison between patients and controls in terms of the apoptosis and cell cycle markers in CD8+ T 
lymphocytes. Although a higher percentage of apoptotic cells as well as cells in S or G2/M phases is 
apparent, this result reaches statistical significance only for cells in G2/M.  
 
 
Figure 4. Summary of the comparison between HH patients and controls in the percentages of CD8+ and CD4+ T 
lymphocytes in apoptosis (left graph) and in cycle phases S and G2M (right graph). * Significantly different 
(p=0,0025). 
 
The increased number of cells in G2/M, however, does not necessarily mean that there are more cells 
in mitosis, but could also mean that there are more cells arrested in G2 for DNA repair. If this is the case, it 
suggests that patients may be somehow responding to oxidative injury, such as the case iron induced cell 
death. A similar model was addressed by Porto B. et al in a study about the genotoxic effect of 
diepoxybutane (DEB) where HH patients´ lymphocytes were shown to have a lower DEB-induced 
chromosome instability possibly due to an adaptive response of the HH lymphocytes with increased DNA 
repair (Porto, B et al. 2007). Further studies of lymphocyte cell division in HH patients should be designed in 
order to clarify if indeed, HH patients have more proliferating cells to compensate for an increased iron 
induced apoptosis or if they simply accumulate more cells arrested in G2 for DNA repair and, as a 
consequence, have a decreased total number of functional lymphocytes. 
* 
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CONCLUSION 
 
The present research, although it could not clarify the mechanism underlying the abnormalities in T 
lymphocyte counts of HH patients, reinforced the notion that there are phenotypic changes in this cell 
population, possibly reflecting a response to iron induced cell death.  
Considering the fact that lymphocyte counts have a consistent pattern of correlation with clinic of 
HH, this might be considered as a step into a better comprehension of this heterogeneity.  
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